ABCG2 and cancer: However, this cost appears lower than the metabolic cost of overexpressing BCR::ABL1 as a resistance mechanism; once translated, each ABCG2 transporter is able to transport many dasatinib molecules out of the cancer cell cytosol, whereas for resistance mediated by BCR::ABL1 overexpression alone, an entire BCR::ABL1 protein must be translated to counteract each TKI molecule.